Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FNTA | P49354 | 3/20 | 0.39 |
| ▸ | FNTB | P49356 | 3/20 | 0.39 |
| ▸ | CASP3 | P42574 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 3/20 | 0.37 |
| ▸ | GAA | P10253 | 3/20 | 0.37 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.35 |
| ▸ | ITGAV | P06756 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | KLK7 | P49862 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL351696 | 1.00 | FNTA (0.39) | FNTAFNTBCASP3MAPTGAA | |
| SCHEMBL15967508 | 0.91 | FNTA (0.39) | FNTAFNTBCASP3MAPTGAA | |
| SCHEMBL350365 | 0.91 | FNTA (0.39) | FNTAFNTBCASP3MAPTGAA | |
| SCHEMBL15967510 | 0.91 | FNTA (0.39) | FNTAFNTBCASP3MAPTGAA | |
| SCHEMBL349375 | 0.91 | FNTA (0.39) | FNTAFNTBCASP3MAPTGAA | |
| Arbaclofen Placarbil SCHEMBL2472988 | 0.88 | GABBR2 (0.47) | FNTAFNTBMAPTGAAKMT2A | |
| Arbaclofen Placarbil SCHEMBL351833 | 0.88 | GABBR2 (0.47) | FNTAFNTBMAPTGAAKMT2A | |
| Arbaclofen Placarbil SCHEMBL349961 | 0.88 | GABBR2 (0.47) | FNTAFNTBMAPTGAAKMT2A | |
| Arbaclofen Placarbil SCHEMBL638204 | 0.88 | GABBR2 (0.47) | FNTAFNTBMAPTGAAKMT2A | |
| Arbaclofen Placarbil SCHEMBL3375708 | 0.88 | GABBR2 (0.47) | FNTAFNTBMAPTGAAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120016021-A1 | METHODS OF TREATING FRAGILE X SYNDROME, DOWN'S SYNDROME, AUTISM AND RELATED DISORDERS | XENOPORT, INC. (US) | 2012-01-19 | — | — | US | claimed |
| US-20120016021-A1 | METHODS OF TREATING FRAGILE X SYNDROME, DOWN'S SYNDROME, AUTISM AND RELATED DISORDERS | XENOPORT, INC. (US) | 2012-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120016021-A1 | METHODS OF TREATING FRAGILE X SYNDROME, DOWN'S SYNDROME, AUTISM AND RELATED DISORDERS | GABBR2, GABBR1, GABRB1 | FNTA 3741/4885FNTB 1907/4885CASP3 2282/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.